Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Ara Metjian

TitleAssociate Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Abou-Ismail MY, Zhang C, Presson AP, Chaturvedi S, Antun AG, Farland AM, Woods R, Metjian A, Park YA, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Akwaa F, Clover T, Baumann Kreuziger L, Sridharan M, Go RS, McCrae KR, Upreti HV, Gangaraju R, Kocher NK, Zheng XL, Raval JS, Masias C, Cataland SR, Johnson AD, Davis E, Evans MD, Mazepa M, Lim MY. A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry. Blood Adv. 2024 02 13; 8(3):620-623. PMID: 38100454.
      View in: PubMed
    2. Tarantino MD, Hardesty B, Metjian A, Ortel TL, Chen J, Badejo K, Ma A, Cuker A, Rajasekhar A, Friedman KD, Janbain M. Real-world safety and effectiveness of recombinant porcine sequence factor VIII in acquired haemophilia A: A non-interventional, post-authorization safety study. Haemophilia. 2023 Sep; 29(5):1259-1268. PMID: 37584309.
      View in: PubMed
    3. Metjian A. iTTP: more long-term consequences. Blood. 2023 01 19; 141(3):216-217. PMID: 36656614.
      View in: PubMed
    4. Shah H, Chen H, Pan XZ, Metjian A, Brodsky RA, Braunstein EM, Chaturvedi S. C5 inhibition allows continued antineoplastic therapy in cancer- and chemotherapy-associated thrombotic microangiopathy. Blood Adv. 2022 Dec 13; 6(23):6071-6074. PMID: 35914225.
      View in: PubMed
    5. Scully M, de la Rubia J, Pavenski K, Metjian A, Kn?bl P, Peyvandi F, Cataland S, Coppo P, Kremer Hovinga JA, Minkue Mi Edou J, De Passos Sousa R, Callewaert F, Gunawardena S, Lin J. Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study. J Thromb Haemost. 2022 12; 20(12):2810-2822. PMID: 36138517.
      View in: PubMed
    6. Chaturvedi S, Antun AG, Farland AM, Woods R, Metjian A, Park YA, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Akwaa F, Clover T, Baumann Kreuziger L, Sadler JE, Sridharan M, Go RS, McCrae KR, Upreti HV, Liu A, Lim MY, Gangaraju R, Zheng XL, Raval JS, Masias C, Cataland SR, Johnson A, Davis E, Evans MD, Mazepa MA. Race, rituximab, and relapse in TTP. Blood. 2022 09 22; 140(12):1335-1344. PMID: 35797471.
      View in: PubMed
    7. Josephson CD, Goldstein S, Askenazi D, Cohn CS, Spinella PC, Metjian A, Fasano RM, Music-Aplenc L. Safety and tolerability of solvent/detergent-treated plasma for pediatric patients requiring therapeutic plasma exchange: An open-label, multicenter, postmarketing study. Transfusion. 2022 02; 62(2):396-405. PMID: 34931321.
      View in: PubMed
    8. Peyvandi F, Cataland S, Scully M, Coppo P, Knoebl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F. Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Adv. 2021 04 27; 5(8):2137-2141. PMID: 33881463.
      View in: PubMed
    9. Yuan X, Yu J, Gerber G, Chaturvedi S, Cole M, Chen H, Metjian A, Sperati CJ, Braunstein EM, Brodsky RA. Ex vivo assays to detect complement activation in complementopathies. Clin Immunol. 2020 12; 221:108616. PMID: 33148511.
      View in: PubMed
    10. Hanlon A, Metjian A. Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura. Ther Adv Hematol. 2020; 11:2040620720902904. PMID: 32095224.
      View in: PubMed
    11. Knoebl P, Cataland S, Peyvandi F, Coppo P, Scully M, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. J Thromb Haemost. 2020 02; 18(2):479-484. PMID: 31691462.
      View in: PubMed
    12. Zwicker JI, Muia J, Dolatshahi L, Westfield LA, Nieters P, Rodrigues A, Hamdan A, Antun AG, Metjian A, Sadler JE. Adjuvant low-dose rituximab and plasma exchange for acquired TTP. Blood. 2019 09 26; 134(13):1106-1109. PMID: 31331919.
      View in: PubMed
    13. Scully M, Cataland SR, Peyvandi F, Coppo P, Kn?bl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019 01 24; 380(4):335-346. PMID: 30625070.
      View in: PubMed
    14. Diep R, Metjian A. A rare CALR variant mutation and a review of CALR in essential thrombocythemia. J Thromb Thrombolysis. 2018 Apr; 45(3):457-462. PMID: 29411299.
      View in: PubMed
    15. Onwuemene OA, Grambow SC, Patel CB, Mentz RJ, Milano CA, Rogers JG, Metjian AD, Arepally GM, Ortel TL. Indications for and outcomes of therapeutic plasma exchange after cardiac transplantation: A single center retrospective study. J Clin Apher. 2018 Aug; 33(4):469-479. PMID: 29524240.
      View in: PubMed
    16. Tanhehco YC, Arepally G, Metjian A. Novel therapeutic approaches for thrombotic thrombocytopenic purpura. Curr Opin Hematol. 2017 Nov; 24(6):521-528. PMID: 28759473.
      View in: PubMed
    17. Abbes S, Metjian A, Gray A, Martinu T, Snyder L, Chen DF, Ellis M, Arepally GM, Onwuemene O. Human Leukocyte Antigen Sensitization in Solid Organ Transplantation: A Primer on Terminology, Testing, and Clinical Significance for the Apheresis Practitioner. Ther Apher Dial. 2017 Oct; 21(5):441-450. PMID: 28880430.
      View in: PubMed
    18. Metjian A, Tanhehco YC, Aqui N, Bhoj VG, Jamensky L, Marques MB, Onwuemene O, Pham HP, Arepally GM. The thrombotic microangiopathy Registry of North America: A United States multi-institutional TMA network. J Clin Apher. 2016 Oct; 31(5):448-53. PMID: 26575088.
      View in: PubMed
    19. Metjian AD. rVWF: treatment finally reaches the modern age. Blood. 2015 Oct 22; 126(17):1975-6. PMID: 26494919.
      View in: PubMed
    20. Nipp R, Mitchell A, Pishko A, Metjian A. Waldenstr?m macroglobulinemia in hepatitis C: case report and review of the current literature. Case Rep Oncol Med. 2014; 2014:165670. PMID: 25247100.
      View in: PubMed
    21. Patil AS, Dotters-Katz SK, Metjian AD, James AH, Swamy GK. Use of a thrombopoietin mimetic for chronic immune thrombocytopenic purpura in pregnancy. Obstet Gynecol. 2013 Aug; 122(2 Pt 2):483-485. PMID: 23884268.
      View in: PubMed
    22. Sood SL, Cuker A, Wang C, Metjian AD, Chiang EY, Soucie JM, Konkle BA. Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A. Haemophilia. 2013 Jul; 19(4):595-601. PMID: 23534856.
      View in: PubMed
    23. Lee G, Duan-Porter W, Metjian AD. Acquired, non-amyloid related factor X deficiency: review of the literature. Haemophilia. 2012 Sep; 18(5):655-63. PMID: 23437437.
      View in: PubMed
    24. Whitlatch NL, Kong DF, Metjian AD, Arepally GM, Ortel TL. Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood. 2010 Sep 09; 116(10):1761-6. PMID: 20508160.
      View in: PubMed
    25. Metjian A, Abrams CS. New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents. Biologics. 2009; 3:499-513. PMID: 20054440.
      View in: PubMed
    26. Metjian AD, Wang C, Sood SL, Cuker A, Peterson SM, Soucie JM, Konkle BA. Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease. Haemophilia. 2009 Jul; 15(4):918-25. PMID: 19473418.
      View in: PubMed
    27. Metjian A, Lim W. ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis? Hematology Am Soc Hematol Educ Program. 2009; 247-9. PMID: 20008205.
      View in: PubMed
    28. Metjian A, Abrams CS. New insights and therapeutics for immune-mediated thrombocytopenia. Expert Rev Cardiovasc Ther. 2008 Jan; 6(1):71-84. PMID: 18095908.
      View in: PubMed
    29. Metjian A, Roll RL, Ma AD, Abrams CS. Agonists cause nuclear translocation of phosphatidylinositol 3-kinase gamma. A Gbetagamma-dependent pathway that requires the p110gamma amino terminus. J Biol Chem. 1999 Sep 24; 274(39):27943-7. PMID: 10488142.
      View in: PubMed
    30. Ma AD, Metjian A, Bagrodia S, Taylor S, Abrams CS. Cytoskeletal reorganization by G protein-coupled receptors is dependent on phosphoinositide 3-kinase gamma, a Rac guanosine exchange factor, and Rac. Mol Cell Biol. 1998 Aug; 18(8):4744-51. PMID: 9671484.
      View in: PubMed
    Metjian's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (167) concept(s)
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)